3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
17
Colorectal Neoplasms
13
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Neoplasm Metastasis
4
Skin Neoplasms
3
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Rectal Neoplasms
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Skin Diseases
1
Rectal Diseases
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Diseases
1
Colonic Diseases
1
Brain Neoplasms
1
Interventions
binimetinib
2
Watchful Waiting
2
Aminolevulinic Acid
2
palbociclib
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Paclitaxel
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Dacarbazine
1
Cantharidin
1
BF-200 ALA
1
Anastrozole
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Diseases
×
encorafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA